Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

National Institutes of Health Nationwide (Federal)

Tell us about your organization and we'll show you whether this grant fits, and why.

Check if you're eligible Save this grant

Free to start. No credit card required.

Deadline

November 19, 2026

Region

Nationwide (Federal)

Funder type

Federal Government

For

Nonprofits & businesses

Sectors

Health & Human Services

About this program

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) — U.S. federal funding opportunity (PAR-25-226) from National Institutes of Health. See grants.gov for full eligibility and details.

Official program page Last verified October 5, 2026 by the Happy Grants engine

Is this grant worth your time?

Create a free account and Happy Grants scores this program, and 2,300+ others, against your organization’s profile in about a minute, with the reasons explained.

See your match score, free

Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)

About this program

Is this grant worth your time?

Similar grants